BACKGROUND: African-Americans (AAs) are predisposed to non-diabetic (non-DM) end-stage renal disease (ESRD), and studies have shown a genetic component to this risk. Rare mutations in ACTN4 (α-actinin-4), an actin-binding protein expressed in podocytes, cause familial focal segmental glomerulosclerosis. METHODS: We assessed the contribution of coding variants in ACTN4 to non-DM ESRD risk in AAs. Nineteen exons, 2,800 bases of the promoter and 392 bases of the 3' untranslated region of ACTN4 were sequenced in 96 AA non-DM ESRD cases and 96 non-nephropathy controls (384 chromosomes). Sixty-seven single-nucleotide polymorphisms (SNPs) including 51 novel SNPs were identified. The SNPs comprised 33 intronic, 21 promoter, 12 exonic, and one 3' variant. Sixty-two of the SNPs were genotyped in 296 AA non-DM ESRD cases and 358 non-nephropathy controls. RESULTS: One SNP, rs10404257, was associated with non-DM ESRD (p < 1.0E-4, odds ratio, OR = 0.76; confidence interval, CI = 0.59-0.98; additive model). Forty-seven SNPs had minor allele frequencies <5%. These SNPs were segregated into risk and protective SNPs, and each category was collapsed into a single marker, designated by the presence or absence of any rare allele. The presence of any rare allele at a risk SNP was significantly associated with non-DM ESRD (p = 0.001, dominant model). The SNPs with the strongest evidence for association (n = 20) were genotyped in an independent set of 467 non-DM ESRD cases and 279 controls. Although rs10404257 was not associated in this replication sample, when the samples were combined, rs10404257 was modestly associated (p = 0.032, OR = 0.78, CI = 0.63-0.98; dominant model). SNPs were tested for interaction with markers in the APOL1 gene, previously associated with non-DM ESRD in AAs, and rs10404257 was modestly associated (p = 0.0261, additive model). CONCLUSIONS: This detailed evaluation of ACTN4 variation revealed limited evidence of association with non-DM ESRD in AAs.
BACKGROUND: African-Americans (AAs) are predisposed to non-diabetic (non-DM) end-stage renal disease (ESRD), and studies have shown a genetic component to this risk. Rare mutations in ACTN4 (α-actinin-4), an actin-binding protein expressed in podocytes, cause familial focal segmental glomerulosclerosis. METHODS: We assessed the contribution of coding variants in ACTN4 to non-DM ESRD risk in AAs. Nineteen exons, 2,800 bases of the promoter and 392 bases of the 3' untranslated region of ACTN4 were sequenced in 96 AA non-DM ESRD cases and 96 non-nephropathy controls (384 chromosomes). Sixty-seven single-nucleotide polymorphisms (SNPs) including 51 novel SNPs were identified. The SNPs comprised 33 intronic, 21 promoter, 12 exonic, and one 3' variant. Sixty-two of the SNPs were genotyped in 296 AA non-DM ESRD cases and 358 non-nephropathy controls. RESULTS: One SNP, rs10404257, was associated with non-DM ESRD (p < 1.0E-4, odds ratio, OR = 0.76; confidence interval, CI = 0.59-0.98; additive model). Forty-seven SNPs had minor allele frequencies <5%. These SNPs were segregated into risk and protective SNPs, and each category was collapsed into a single marker, designated by the presence or absence of any rare allele. The presence of any rare allele at a risk SNP was significantly associated with non-DM ESRD (p = 0.001, dominant model). The SNPs with the strongest evidence for association (n = 20) were genotyped in an independent set of 467 non-DM ESRD cases and 279 controls. Although rs10404257 was not associated in this replication sample, when the samples were combined, rs10404257 was modestly associated (p = 0.032, OR = 0.78, CI = 0.63-0.98; dominant model). SNPs were tested for interaction with markers in the APOL1 gene, previously associated with non-DM ESRD in AAs, and rs10404257 was modestly associated (p = 0.0261, additive model). CONCLUSIONS: This detailed evaluation of ACTN4 variation revealed limited evidence of association with non-DM ESRD in AAs.
Authors: J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: Astrid Weins; Peter Kenlan; Stephanie Herbert; Tu C Le; Ivan Villegas; Bernard S Kaplan; Gerald B Appel; Martin R Pollak Journal: J Am Soc Nephrol Date: 2005-10-26 Impact factor: 10.121
Authors: Savita V Dandapani; Hikaru Sugimoto; Benjamin D Matthews; Robert J Kolb; Sumita Sinha; Robert E Gerszten; Jing Zhou; Donald E Ingber; Raghu Kalluri; Martin R Pollak Journal: J Biol Chem Date: 2006-11-02 Impact factor: 5.157
Authors: Barry I Freedman; Carl D Langefeld; Stephen S Rich; Christopher J Valis; Michèle M Sale; Adrienne H Williams; W Mark Brown; Stephanie R Beck; Pamela J Hicks; Donald W Bowden Journal: J Am Soc Nephrol Date: 2004-10 Impact factor: 10.121
Authors: K Honda; T Yamada; R Endo; Y Ino; M Gotoh; H Tsuda; Y Yamada; H Chiba; S Hirohashi Journal: J Cell Biol Date: 1998-03-23 Impact factor: 10.539
Authors: June Yao; Tu Cam Le; Claudine H Kos; Joel M Henderson; Phillip G Allen; Bradley M Denker; Martin R Pollak Journal: PLoS Biol Date: 2004-06-15 Impact factor: 8.029
Authors: Shanika Nanayakkara; S T M L D Senevirathna; Nipuna B Parahitiyawa; Tilak Abeysekera; Rohana Chandrajith; Neelakanthi Ratnatunga; Toshiaki Hitomi; Hatasu Kobayashi; Kouji H Harada; Akio Koizumi Journal: Environ Health Prev Med Date: 2015-06-25 Impact factor: 3.674